ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Increase in Short Interest

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 250,200 shares, an increase of 114.2% from the March 31st total of 116,800 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company’s stock are short sold.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $10.00 price objective (down from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of ASLAN Pharmaceuticals in a research report on Tuesday.

ASLAN Pharmaceuticals Price Performance

ASLN opened at $0.45 on Friday. The company has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $0.72. The firm has a market cap of $7.32 million, a P/E ratio of -0.16 and a beta of 1.45. ASLAN Pharmaceuticals has a 1-year low of $0.39 and a 1-year high of $4.69.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its earnings results on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. Equities analysts anticipate that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current year.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.